Hazlett, Burt & Watson’s BridgeBio Pharma BBIO Stock Holding History

Hazlett, Burt & Watson’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-26	Closed	-$2K	–	907
2026 Q1	$2K	Hold	26	–	–	﹤0.01%	846
2025 Q4	$2K	Buy	+26	New	+$1.71K	﹤0.01%	856

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Hazlett, Burt & Watson's BBIO Position: Q2 2026 in Review

Hazlett, Burt & Watson sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 26 shares — an estimated $2K sold.

Hazlett, Burt & Watson first reported a position in BBIO in Q4 2025 and held it in 2 quarters. The position peaked at $2K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Hazlett, Burt & Watson reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
Hazlett, Burt & Watson sold 26 BridgeBio Pharma shares in Q2 2026, an estimated $2K.
Hazlett, Burt & Watson first reported a position in BridgeBio Pharma in Q4 2025 and held it in 2 quarters.
Hazlett, Burt & Watson's BridgeBio Pharma position peaked at $2K in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2026, filed 30 Jul 2026.